BELITE BIO, INC
Business
Belite Bio is a clinical-stage biopharmaceutical company developing novel therapeutics for degenerative retinal diseases and metabolic disorders. The company's lead candidate tinlarebant (LBS-008) is an RBP4 antagonist in Phase 3 development for Stargardt disease type 1 (STGD1) and geographic atrophy (GA) associated with dry age-related macular degeneration; a Phase 3 trial in GA was fully enrolled with 530 subjects. A second candidate, LBS-009, is in preclinical development for non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes and gout. Belite holds an exclusive worldwide license to an RBP4 intellectual property portfolio from Columbia University.
Summary from 20-F filed 2026-03-31
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-77.61M |
| Total assets | $780.56M |
| Total liabilities | $10.07M |
| Stockholders' equity | $770.49M |
| Operating cash flow | $-36.99M |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is BELITE BIO, INC's CIK number?
BELITE BIO, INC's SEC CIK number is 0001889109 (1889109). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find BELITE BIO, INC's SEC filings?
All of BELITE BIO, INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.